Apellis Pharmaceuticals Q2 2024 GAAP EPS $(0.30) Beats $(0.32) Estimate, Sales $154.600M Miss $191.511M Estimate
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals (NASDAQ:APLS) reported Q2 2024 GAAP EPS of $(0.30), beating the estimate of $(0.32). However, sales of $154.6M missed the $191.511M estimate, despite a 62.79% increase from the same period last year.
August 01, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Apellis Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.30), beating the estimate of $(0.32). However, sales of $154.6M missed the $191.511M estimate, despite a 62.79% increase from the same period last year.
While Apellis Pharmaceuticals beat EPS estimates, the significant miss on sales estimates could create mixed reactions in the market. The YoY sales increase is a positive sign, but missing the sales target by 19.27% may concern investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100